TherapeuticsMD Inc

For the period ended Mar 31, 2025. Filed May 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(Unaudited - in thousands)

	Three Months Ended March 31,
	2025	2024
Cash flows from operating activities:
Net loss	$(653)	$(734)
Less: (loss) income from discontinued operations, net of income taxes	(17)	75
Net loss from continuing operations	(636)	(809)
Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities:
Depreciation and amortization	95	133
Write-off of patents and trademarks	88	—
Share-based compensation	23	111
Other	154	186
Changes in operating assets and liabilities:
Other assets	502	629
Prepaid and other current assets	433	34
Accounts payable	(82)	112
Accrued expenses and other current liabilities	274	(413)
Lease liabilities	(203)	(213)
Other non-current liabilities	51	1
Total adjustments	1,335	580
Net cash provided by (used in) continuing operating activities	699	(229)
Discontinued operations:
Net cash (used in) provided by operating activities	(13)	240
Net cash (used in) provided by discontinued operations	(13)	240
Net increase in cash	686	11
Cash and cash equivalents - continuing operations, beginning of period	5,059	4,327
Total cash and cash equivalents, end of period	$5,745	$4,338

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.